John P Maxwell

10PUBLICATIONS
105CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

|May 18, 2026
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of <i>MTAP</i>-Deleted Cancers.

|Apr 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers.

|Aug 29, 2025
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang

|Jun 24, 2025
MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models.

Xiaochun Zhang, Dana C Borcherding, Minjie Zhang

|Mar 04, 2025
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with <i>MTAP</i> Deletion.

Kevin M Cottrell, Kimberly J Briggs, Alice Tsai

Pageof 2

Frequent Collaborators

9 joint publications

Douglas A Whittington

5 joint publications

Minjie Zhang

5 joint publications

Kevin M Cottrell

5 joint publications

Yi Yu